Browse every peptide.

A long-acting GLP-1 receptor agonist studied for its effects on appetite, satiety, and glucose regulation.

A dual GIP and GLP-1 receptor agonist with strong effects on appetite, glucose handling, and body composition.

An investigational triple agonist of GLP-1, GIP, and glucagon receptors producing some of the largest weight-loss results recorded in trials.

A pentadecapeptide derived from a gastric protein, widely studied for its regenerative and cytoprotective effects.

A selective ghrelin receptor agonist that triggers clean, pulsatile GH release without significant cortisol or prolactin spikes.

A GHRH analog designed for long-acting stimulation of natural growth hormone production.

A naturally occurring copper-binding tripeptide widely studied in dermatology and increasingly popular in longevity protocols.

A non-peptide ghrelin mimetic taken orally to elevate GH and IGF-1 over a 24-hour window.

A synthetic fragment of Thymosin Beta-4 widely used in injury recovery research and frequently stacked with BPC-157.

A small-molecule oral GLP-1 receptor agonist studied as a needle-free alternative to injectable incretin therapy.

A synthetic melanocortin agonist studied for its effects on skin pigmentation and sexual function.

A synthetic ACTH-derived peptide developed in Russia and widely studied for cognitive enhancement and stroke recovery.

An FDA-approved stabilized GHRH analog used to reduce visceral fat, with broader interest in body composition and cognition research.

A GHRH (1–29) analog that stimulates the body's natural growth hormone production through normal pituitary feedback.

A long-acting modified analog of insulin-like growth factor 1 with extended half-life and reduced binding-protein affinity.

A mitochondrial-derived peptide studied for metabolic regulation, insulin sensitivity, and exercise capacity.

A myostatin-binding protein studied for its potential to drive significant muscle hypertrophy by removing the body's natural growth ceiling.

A modified C-terminal fragment of human growth hormone designed for fat-loss effects without the broader anabolic action of full HGH.

A potent synthetic ghrelin receptor agonist that produces one of the strongest GH pulses among the GHRP family.

A potent ghrelin agonist that drives GH release while also significantly increasing appetite.

A first-generation GHRP with very strong appetite-stimulating effects, often used in older bulking protocols.

A short peptide derived from kisspeptin, the master regulator of the reproductive hormone axis.

An FDA-approved melanocortin agonist for hypoactive sexual desire, acting centrally on arousal pathways rather than vasculature.

A synthetic peptide modeled on tuftsin, used in Russia for anxiety and cognitive enhancement without the sedation of typical anxiolytics.

A synthetic tetrapeptide developed in Russia, studied extensively for telomerase activation and aging biomarkers.

A naturally occurring thymic peptide used clinically as an immunomodulator for chronic viral infections and immune support.

A short tripeptide fragment of α-MSH studied for anti-inflammatory effects in the gut and skin without pigmentation effects.

A naturally occurring antimicrobial peptide of the cathelicidin family with broad-spectrum activity against bacteria, viruses, and fungi.

The 'bonding hormone' used clinically in obstetrics and increasingly studied in research for its effects on social cognition and mood.

A designer peptide that selectively triggers apoptosis in senescent cells, an emerging anti-aging strategy.

A nine-amino-acid neuropeptide first identified for its sleep-promoting effects, now studied for stress and circadian regulation.

A long-acting amylin analog developed to be combined with semaglutide for enhanced weight loss (CagriSema).

A dual GLP-1 / glucagon receptor agonist developed by Innovent and Eli Lilly for type 2 diabetes and weight loss.

A weekly dual GLP-1 / glucagon receptor agonist developed by Boehringer Ingelheim and Zealand Pharma for obesity and MASH.